Neutrophil elastase has been implicated in COPD for many years. The enzyme
has a variety of effects that can contribute to the disease process, partic
ularly in lung degradation and mucus secretion. Several approaches have bee
n taken to the design and delivery of elastase inhibitors to the lung. The
pros and cons of each are discussed in this review.